Market Analysis

From the Desk of Steve Strazza @Sstrazza

Welcome to The 2 to 100 Club.

In this scan, we look to identify the strongest growth stocks as they climb the market-cap ladder from small- to mid- to large- and, ultimately, to mega-cap status (over $200B).

Once they graduate from small-cap to mid-cap status (over $2B), they come on our radar. Likewise, when they surpass the roughly $30B mark, they roll off our list.

But the scan doesn't just end there.

We only want to look at the strongest growth industries in the market, as that is typically where these potential 50-baggers come from.

In today’s Daily Digest, we’ll review the following:

1. No new positions today.
2. Adjustment to XLI position.
3. No exits since the last report.
4. Current status of open campaigns.
5. NEW: Volatility Snapshot.

Let’s dig in!

From the Desk of Steve Strazza @Sstrazza

Last week, we outlined a short squeeze in Phathom Pharmaceuticals $PHAT, which has been working for us.

It doesn't seem like the market is finished squeezing the short sellers out of their biotechnology positions.

Today, we're discussing yet another biotech stock that has a ridiculously high days-to-cover ratio and short interest.

More importantly, the risk couldn't be more well-defined.

So, we're stepping up to the plate and taking another swing at a short squeeze.

In today’s Daily Digest, we’ll review the following:

1. No new positions today.
2. Adjustment to XLP position.
3. No exits since the last report.
4. Current status of open campaigns.
5. NEW: Volatility Snapshot.

Let’s dig in!

After Covid there was no sector that did better than Consumer Discretionary stocks.

Locking everyone down and sending them all a check to go spend, as it turns out, was great for the Consumer Discretionary sector. 

And then 2021 ended and the correction in Consumer began...

Years in the making, here is the massive top in Consumer Discretionary relative to the S&P500 that's got people talking...

Did you hear about the massive top in Semiconductors?

Everyone is talking about it on the internets. So it must be true. 

Seems the easy call here to make is to say "that was it". The Semiconductor story and the bull market as we know it is over...'

One of the things they teach you in the first week of Technical Analysis kindergarten is that infamous Head & Shoulders top.

The market continues to send signals that nearby risks are elevated, and there is no clear indication to us in which direction the next sustained move will come.

So, as has been the vibe for the past couple of weeks, I'm looking for trades that can offer my portfolio some diversification. 

In today’s Daily Digest, we’ll review the following:

1. No new positions today.
2. Adjustment to XLC position.
3. No exits since the last report.
4. Current status of open campaigns.
5. NEW: Volatility Snapshot.

Let’s dig in!

Last month, we discussed the Palladium ETF $PALL hitting fresh 7-year lows, breaching a critical support level.

However, the bears could not gain any downside momentum, and it seems like we're nearing a cyclical trough.

Commercial hedgers have never carried a larger net-long position. Historically, it has been prudent to not bet against the smart money in commodities markets.

And one of our favorite long-term momentum indicators, the monthly MACD, has now given us a buy signal. That said, it's still a bit messy in the short term.

Let's talk about it.

I've anticipated sideways price action for a month.

This continues as my intermediate outlook (months) has shifted from bullish to neutral as Bitcoin lost $56,000 and stocks appear as if they need time to improve.

My short-term outlook (weeks) moves from neutral to bullish, with Bitcoin and Ethereum at their lows and negative funding set us up for a bounce. I remain long on tokens like HNT, SOL, and BLUR holding support, but await further market shape before becoming overly bullish.